These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 1962909)
1. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin. Shimotori T; Sakuragawa N Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909 [TBL] [Abstract][Full Text] [Related]
2. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition. Ofosu FA; Smith LM; Anvari N; Blajchman MA Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms for the anticoagulant effect of heparin and related polysaccharides. Ofosu FA Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155 [TBL] [Abstract][Full Text] [Related]
4. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities. Peyrou V; Béguin S; Boneu B; Hemker HC Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588 [TBL] [Abstract][Full Text] [Related]
5. Study of low molecular weight heparin effect on the relation between anticoagulant activity and antithrombin III affinity. Hamano S; Nishiyama M; Kikuchi S; Komatsu H; Miyata H; Ikeda S; Sakuragawa N Thromb Res; 1992 May; 66(4):299-307. PubMed ID: 1329257 [TBL] [Abstract][Full Text] [Related]
6. The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions. Barrowcliffe TW; Le Shirley Y Thromb Haemost; 1989 Nov; 62(3):950-4. PubMed ID: 2556814 [TBL] [Abstract][Full Text] [Related]
7. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence. Bohner J; von Pape KW; Blaurock M Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789 [TBL] [Abstract][Full Text] [Related]
8. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Brieger D; Dawes J Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589 [TBL] [Abstract][Full Text] [Related]
9. Effect of low molecular weight heparin preparations on the inhibition of thrombin by heparin cofactor II. Tollefsen DM; Sugimori T; Maimone MM Semin Thromb Hemost; 1990 Oct; 16 Suppl():66-70. PubMed ID: 1962908 [TBL] [Abstract][Full Text] [Related]
10. Effects of sulfation on antithrombin-thrombin/factor Xa interactions in semisynthetic low molecular weight heparins. Sissi C; Naggi A; Torri G; Palumbo M Semin Thromb Hemost; 2001 Oct; 27(5):483-7. PubMed ID: 11668417 [TBL] [Abstract][Full Text] [Related]
11. Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues. Jeske W; Fareed J Semin Thromb Hemost; 1993; 19 Suppl 1():241-7. PubMed ID: 8362268 [TBL] [Abstract][Full Text] [Related]
12. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto. Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590 [TBL] [Abstract][Full Text] [Related]
13. [Effect of heparin cofactor II on the antithrombin III activities measured by thrombin methods or factor Xa methods--fundamental studies and clinical studies using the plasma of pregnant women]. Akai Y; Shiga S; Tohyama K; Shimatsu A; Ichiyama S Rinsho Byori; 2000 Sep; 48(9):867-71. PubMed ID: 11051806 [TBL] [Abstract][Full Text] [Related]
14. The mode of action of CY216 and CY222 in plasma. Béguin S; Wielders S; Lormeau JC; Hemker HC Thromb Haemost; 1992 Jan; 67(1):33-41. PubMed ID: 1319616 [TBL] [Abstract][Full Text] [Related]
15. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases. Melo FR; Mourão PA Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological activities of heparins obtained from different tissues: enrichment of heparin fractions with high lipoprotein lipase, antihemolytic and anticoagulant activities by molecular sieving and antithrombin III affinity chromatography. Bianchini P; Osima B; Parma B; Nader HB; Dietrich CP J Pharmacol Exp Ther; 1982 Feb; 220(2):406-10. PubMed ID: 7057400 [TBL] [Abstract][Full Text] [Related]
17. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin. Meddahi S; Bara L; Fessi H; Samama MM Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099 [TBL] [Abstract][Full Text] [Related]
18. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects. Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715 [TBL] [Abstract][Full Text] [Related]
19. The effects of human thrombomodulin on the inactivation of thrombin by its serum inhibitors. Thompson EA; Salem HH Thromb Haemost; 1987 Oct; 58(3):806-10. PubMed ID: 2829375 [TBL] [Abstract][Full Text] [Related]
20. [The antithrombin action of stichopus japonicus acid mucopolysaccharide (Sjamp) is mediated by heparin cofactor II]. Zhang G Zhonghua Xue Ye Xue Za Zhi; 1997 Mar; 18(3):126-9. PubMed ID: 15622771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]